Salim Syed
Stock Analyst at Mizuho
(2.40)
# 2,504
Out of 5,126 analysts
77
Total ratings
45.16%
Success rate
1.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Upgrades: Outperform | $90 → $121 | $108.39 | +11.63% | 1 | Dec 8, 2025 | |
| ASMB Assembly Biosciences | Maintains: Outperform | $29 → $40 | $26.22 | +52.56% | 2 | Nov 20, 2025 | |
| NKTX Nkarta | Maintains: Outperform | $16 → $14 | $2.02 | +593.07% | 8 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $103 → $84 | $62.34 | +34.74% | 7 | May 29, 2025 | |
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $201.18 | -16.00% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $384.32 | -27.14% | 8 | May 7, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $100 → $117 | $152.50 | -23.28% | 7 | May 5, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $13.45 | +63.57% | 5 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $56.15 | +190.29% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $4.88 | +268.85% | 4 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $29.42 | +15.57% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $99 | $48.74 | +103.12% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $68.05 | -22.12% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $2.14 | +881.31% | 5 | Nov 16, 2022 |
Incyte
Dec 8, 2025
Upgrades: Outperform
Price Target: $90 → $121
Current: $108.39
Upside: +11.63%
Assembly Biosciences
Nov 20, 2025
Maintains: Outperform
Price Target: $29 → $40
Current: $26.22
Upside: +52.56%
Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $2.02
Upside: +593.07%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103 → $84
Current: $62.34
Upside: +34.74%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $201.18
Upside: -16.00%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $384.32
Upside: -27.14%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $152.50
Upside: -23.28%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $13.45
Upside: +63.57%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $56.15
Upside: +190.29%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $4.88
Upside: +268.85%
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $29.42
Upside: +15.57%
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $48.74
Upside: +103.12%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $68.05
Upside: -22.12%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $2.14
Upside: +881.31%